Table 1.
Characteristics of patients (n = 227) with valid EGFR test results using two mutation tests.
| Patient Demographics (Wild vs. Mutant) | PANAMutyper Test Result | cobas v2 Test Result | ||||
|---|---|---|---|---|---|---|
| Wild | Mutant | p value | Wild | Mutant | p Value | |
| (n = 130) | (n = 97) | (n = 143) | (n = 84) | |||
| Age a | ||||||
| Median y (range) | 68 (44–85) | 63 (35–83) | p < 0.001 | 68 (44–85) | 63 (35–83) | p < 0.001 |
| Sex b | ||||||
| Male | 89 (39%) | 36 (16%) | p < 0.001 | 99 (44%) | 26 (12%) | p < 0.001 |
| Female | 41 (18%) | 61 (27%) | 44 (19%) | 58 (26%) | ||
| Smoking history b | ||||||
| Never | 57 (25%) | 68 (30%) | p < 0.001 | 61 (27%) | 64 (28%) | p < 0.001 |
| Former | 57 (25%) | 24 (11%) | 66 (29%) | 15 (6.6%) | ||
| Current | 16 (7.0%) | 5 (2.2%) | 16 (7.0%) | 5 (2.2%) | ||
| Histology b | ||||||
| Adenocarcinoma | 83 (37%) | 91 (40%) | p < 0.001 | 90 (40%) | 84 (37%) | p < 0.001 |
| Squamous | 45 (20%) | 6 (2.6%) | 51 (23%) | 0 | ||
| Large cell | 2 (0.9%) | 0 | 2 (0.9%) | 0 | ||
| TNM stage b,c | ||||||
| I | 48 (21%) | 33 (15%) | p = 0.644 | 53 (23%) | 28 (12%) | p = 0.491 |
| II | 22 (9.7%) | 9 (4.0%) | 23 (10%) | 8 (3.5%) | ||
| III | 29 (13%) | 11 (4.8%) | 34 (15%) | 6 (2.6%) | ||
| IV | 31 (14%) | 44 (19%) | 33 (15%) | 42 (19%) | ||
a Independent t-test for EGFR wild vs. EGFR mutant groups diagnosed by the same assay. b Chi-square test for EGFR wild vs. EGFR mutant groups diagnosed by the same assay. c TNM stage was determined at the sample collection (TNM: cancer staging system; T: primary tumor; N: lymph node; M: distant metastasis).